As of 2025-07-15, the Intrinsic Value of ImmuPharma PLC (IMM.L) is -5.73 GBP. This IMM.L valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.03 GBP, the upside of ImmuPharma PLC is -382.41%.
Based on its market price of 2.03 GBP and our intrinsic valuation, ImmuPharma PLC (IMM.L) is overvalued by 382.41%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -5.73 - -5.73 | -5.73 | -382.41% |
| P/E | (6.74) - (7.85) | (7.75) | -481.6% |
| DDM - Stable | (2.30) - (6.29) | (4.30) | -311.7% |
| DDM - Multi | (1.75) - (4.02) | (2.47) | -221.7% |
| Market Cap (mil) | 10.64 |
| Beta | 0.80 |
| Outstanding shares (mil) | 5.24 |
| Enterprise Value (mil) | 10.40 |
| Market risk premium | 5.98% |
| Cost of Equity | 14.59% |
| Cost of Debt | 5.00% |
| WACC | 9.52% |